- Robert Brownlee, PeptiGrowth Inc., United Kingdom
Conventional growth factors and cytokines used in regenerative medicine and cell therapy manufacturing face challenges such as lot-to-lot quality variations, biological impurities, low stability, and high costs. PeptiGrowth Inc. addresses these issues with synthetic peptides that offer superior quality, stability, and function compared to traditional growth factors and cytokines.
Our peptides are completely chemically synthesized and animal component-free, ensuring consistent quality and safety. Established in April 2020, PeptiGrowth aims to revolutionize the industry by providing reliable and efficient solutions. We have successfully launched peptide alternatives for HGF, BDNF, Noggin, VEGF, Wnt3a, EGF, and TPO. These peptides are highly stable, maintaining their efficacy for extended periods.
In this session, we will present application examples of these peptides in cell culture models. Additionally, we will introduce our latest product, an alternative peptide for FGF2 (bFGF), which will be launched at the end of September. Attendees will have the opportunity to review the latest data and insights on this new product. Join us to learn how PeptiGrowth's advanced peptides can enhance your cell therapy and regenerative medicine manufacturing processes.
Session Objectives:
- Understand the advantages of synthetic peptides over conventional growth factors and cytokines
- Discover how highly stable peptides enhance the efficiency of cell therapy and regenerative medicine
- Explore real-world applications of HGF, BDNF, Noggin, VEGF, Wnt3a, EGF, and TPO alternative peptides
- Gain insights into the upcoming FGF2 (bFGF) alternative peptide launching at the end of September
SPONSORED BY:
